viewSeelos Therapeutics

Seelos to seek FDA guidance on Phase III trial for SLS-002 ketamine depression drug

It will seek guidance from the FDA in March for an adaptive Phase III trial of SLS-002

Seelos Therapeutics - Seelos Therapeutics Inc schedules FDA meeting on Phase III trial for SLS-002 ketamine depression drug
Data from ongoing Phase I studies of SLS-002 are expected throughout the first quarter of 2020

Seelos Therapeutics Inc (NASDAQ:SEEL) announced Monday that it has scheduled a meeting with federal regulators as it advances its SLS-002 intranasal racemic ketamine depression drug. 

In a statement, the company said in March, it will seek guidance from the US Food and Drug Administration (FDA) for an adaptive Phase III trial of SLS-002 for Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD). 

“Continued communication with FDA is essential for the development of SLS-002 in this high unmet need of ASIB in MDD,” said CEO Raj Mehra. 

READ: Seelos starts dosing in Phase I study of SLS-002 intranasal ketamine depression drug

“We are diligently striving to advance the program forward as we share the Phase I data from the ongoing studies throughout the first quarter,” he added.

Seelos, based in New York, recently received Fast Track designation for SLS-002 for the treatment of ASIB in patients with MDD.

Data from the ongoing Phase I studies of SLS-002 to evaluate the pharmacokinetics, pharmacodynamics, and drug-drug interactions are expected throughout the first quarter of 2020.

Seelos' stock recently traded 7.5% higher to $1.43 a share in New York. 

--ADDS stock price--

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Seelos Therapeutics

Price: 0.8123 USD

Market: NASDAQ
Market Cap: $43.27 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Seelos Therapeutics named herein, including the promotion by the Company of Seelos Therapeutics in any Content on the Site, the Company...



Seelos Therapeutics rings the Nasdaq opening bell

Seelos Therapeutics Inc (NASDAQ: SEEL) CEO Dr Raj Mehra caught up with Proactive after the clinical-stage biopharmaceutical rung the Nasdaq Stock Market opening bell in Times Square, New York. Dr. Mehra says since listing on the exchange in January, the small company has achieved an...

on 12/8/19

2 min read